Compare Emerson Electric Co. (EMR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Eli Lilly And Co — how do they compare? Emerson Electric Co. trades at $136.76 (market cap $76.31B), while Eli Lilly And Co trades at $1,172.81 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 13.5× Emerson Electric Co.'s market cap, and Emerson Electric Co. pays the higher dividend (1.63%). Which is the better fit depends on your goals.
| EMR | LLY | |
|---|---|---|
Market Cap | $76.31B | $1.03T |
Sector | Industrials | Health |
52-Week High | $161.69 | $1.24K |
52-Week Low | $123.30 | $625.65 |
Enterprise Value | $88.58B | $1.07T |
Dividend Yield | 1.63% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $136.11, showing modest daily gains amid a bearish technical signal. The company maintains solid fundamentals with a 13.35% net income margin and recent earnings beats, though valuation multiples like a P/E of 31.54 appear elevated. Analyst consensus is bullish with a $157.60 price target, but cash flow volatility and a high debt-to-asset ratio of 31.26% in 2025 pose concerns. Recent news highlights upcoming Q3 2026 earnings and growth in the Intelligent Devices segment.
EMR offers a balanced risk-reward profile; strong profitability and analyst support suggest upside, but technical weakness and financial leverage require caution. The stock's trajectory hinges on sustaining earnings momentum and managing debt, with key resistance near $137.
LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.
Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
